Page 7 - DIFDUF

725
accountable for the contents of any advertisement or article.
alone. The Israel Medical Association and the editors of "IMAJ" are not
of the advertisers. Similarly, all articles are the responsibility of the authors
All advertisements in this issue are put forward at the sole responsibility
PERFECTOR
editor-in-chief.
Prywes. During the 32 years of publication. Prof. Prywes served as its
Journal of Medical Sciences that was initiated in 1965 by Prof. Moshe
The Israel Medical Association Journal (IMAJ) is the successor of the Israel
Tel: (972-3) 610-0418, Fax: (972-3) 751-9673, email: imaj@ima.org.il
11th floor, 35 Jabotinsky St., P.O. Box 3566, Ramat Gan 5251108, Israel
Address: Israel Medical Association Journal (IMAJ), 2 Twin Towers,
Tovy Malkin
Editorial Secretary
Judi Felber
Manuscript and Production Editor
Halevy Sima, MD
Our studies [2,3] comprised 50 CRC
Gurman Gabriel, MD
Grotto Itamar, MD
Grossman Ehud, MD
Goddard Gisele, MD
Glick Shimon, MD
Eidelman Leonid, MD
Ciechanover Aaron, MD
Blachar Yoram, MD
Birkenfeld Shlomo, MD
Ben Yehuda Dina, MD
Bentur Yedidia, MD
Belhassen Bernard, MD
Barzilai Asher, MD
Baniel Jack, MD
However, the serological test does not
Balbir-Gurman Alexandra, MD
Ashkenazi Shai, MD
131118-COHANIM - 131118-COHANIM | 1 - B | 18-11-13 | 11:24:13 | SR:-- | Cyan
#131118-COHANIM - 131118-COHANIM | 1 - B | 18-11-13 | 11:24:13 | SR:-- | Black
131118-COHANIM - 131118-COHANIM | 1 - B | 18-11-13 | 11:24:13 | SR:-- | Yellow
Atar Dan, MD
131118-COHANIM - 131118-COHANIM | 1 - B | 18-11-13 | 11:24:13 | SR:-- | Magenta
Amital Howard, MD
Afek Arnon, MD
Abu-Shakra Mahmoud, MD
Associate Editors
Joshua Shemer MD and Gad Keren MD
Editor in chief
Yehuda Shoenfeld MD FRCP
Editorial Board
#
IMAGING LETTERS 1 1 1,2 1 4 1 3 1 1 1 1 Therefore, because active Hp-I, with Thus, casting additional light in the Department of Medicine, Second Medical Clinic, Thessaloniki, Thessaloniki, Macedonia, Greece Ippokration Hospital, Aristotle University of 1 and Panagiotis Katsinelos MD PhD Kotronis MD , Sotirios Anastasiadis MD Elizabeth Vardaka PhD , Georgios Ioannis Venizelos MD PhD , Stergios Arapoglou MD PhD , Nikolaos Kapetanakis M
post-Myocardial Infarction Ventricular Septal Defect: Washington (DC): The National Academies Press; 2006. [Available from https:// 14. Mortaro A, Moretti F, Pascu D, et al. Adverse events detection through Global
Trigger Tool methodology: results from a 5-year study in an Italian Hospital and
doi.org/10.17226/11623]. [Accessed 20 May 2018].
Still a Deadly Complication 30 years after the 3. Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized opportunities to improve interrater reliability. J Patient Saf 2017. [Epub ahead
of print].
patients. Results of the Harvard Medical Practice Study II. N Engl J Med 1991;
324 (6): 377-84.
first Transcatheter Closure 4. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential 15. Karpov A, Parcero C, Mok CP, et al. Performance of trigger tools in identifying
adverse drug events in emergency patients: a validation study. Br J Clin Pharmacol
adverse drug events. Implications for prevention. ADE Prevention Study Group. 2016; 82 (4): 1048-57.
JAMA 1995; 274 (1): 29-34. 16. Carnevali L, Krug B, Amant F, et al. Performance of the adverse drug event Trigger
Florian Rey MD , Thibault Ronchard MD PharD , Jawad Chaara MD and Stéphane Noble MD 1 5. Hug BL, Keohane C, Seger DL, Yoon C, Bates DW. The costs of adverse drug Tool and the global Trigger Tool for identifying adverse drug events: experience
1,2
2
2
events in community hospitals. Jt Comm J Qual Patient Saf 2012; 38 (3): 120-6. in a Belgian hospital. Ann Pharmacother 2013; 47 (11): 1414-9.
1 Cardiology Division, Geneva University Hospital, Geneva, Switzerland 17. Franklin BD, Birch S Schachter, Barber N. Testing a trigger tool as a method of
2 Department of Medicine, Montreal Heart Institute, Montreal, Canada 6. Institute of Medicine (US) Committee on Quality of Health Care in America. detecting harm from medication errors in a UK hospital: a pilot study. Int J Pharm
Crossing the Quality Chasm: A New Health System for the 21st Century.
Washington (DC): National Academies Press (US); 2001. Pract 2010; 18: 305-11.
18. Perez Zapata Al, Gutierrez Samaniego M, Rodriguez Cuellar E, Andres Esteban
7. Connelly TP, Korvek SJ. Computer Provider Order Entry (CPOE). StatPearls EM, Gomez de la Camara A, Ruiz Lopez P. Detection of adverse events in general
[Internet]. Treasure Island (FL): StatPearls Publishing; 2017 Jun–2017 Nov 8. surgery using the “Trigger Tool” methodology. Cir Esp 2015; 93 (2): 84-90.
[Available from https://www.ncbi.nlm.nih.gov/books/NBK470273/]. [Accessed 19. Rozenfled S, Giordani F, Coelho S. Adverse drug events in hospital: pilot study
1 June 2018].
rate [3]. Our clinical case emphasizes the cal management [4]. With an IABP, there with Trigger Tool. Rev Sauide Publica 2013; 47: 1102-11.
KEY WORDS: intracardiac shunt, percutaneous complexity of the management and the may be a decrease in the left-to-right shunt, 8. Leung AA, Keohane C, Amato M, et al. Impact of vendor computerized physician 20. Azaz-Livshits T, Levy M, Sadan B, Shalit M, Geisslinger G, Brune K. Computerized
order entry in community hospitals. J Gen Intern Med 2012; 27 (7): 801-7.
coronary intervention (PCI), surgical transcatheter closure of this type of VSD, afterload, and oxygen consumption. It also 9. Jha AK, Kuperman GJ, Teich JM, et al. Identifying adverse drug events: surveillance of adverse drug reactions in hospital: pilot study. Br J Clin Pharmacol
1998; 45 (3): 309-14.
closure, transcatheter closure, especially 1 week after a myocardial infarc- increases the coronary perfusion. In cases development of a computer-based monitor and comparison with chart review 21. Levy M, Azaz-Livshits T, Sadan B, Shalit M, Geisslinger G, Brune K. Computerized
ventricular septal defect (VSD) tion. Successful closure could decrease the of refractory cardiogenic shock, a veno- and stimulated voluntary report. J Am Med Inform Assoc 1998; 5 (3): 305-14. surveillance of adverse drug reactions in hospital: implementation. Eur J Clin
IMAJ 2018; 20: 720–721 30 day mortality rate to 30–40%. arterial extracorporeal membrane oxygen- 10. Institute of Healthcare Improvement. Trigger Tool for measuring adverse Pharmacol 1999; 54 (11): 887-92.
drug events. 2004. [Available from http://www.ini.org/resrources/pages/tools/
A diagnosis of VSD should be con- ation (ECMO) should be considered. triggertoolformeasuringadversedrugevents.aspx]. [Accessed 8 Aug 2014]. 22. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized
patients. Adverse drug events prevention study group. JAMA 1997; 277: 307-11.
sidered in cases of pathologic cardiac We describe a clinical case to empha- 11. De Almeida SM, Romulado A, de Abreu Ferraresi A, Zelezoglo GR, Marra AR, 23. Zimlichman E, Keohane C, Franz C, et al. Return on investment for vendor
ost-myocardial infarction (MI) ven- auscultation and confirmed by emergent size the complexity of the management of Edmond MB. Use of a trigger tool to detect drug reactions in an emergency computerized physician order entry in four community hospitals: the importance
department. BMC Pharmacol Toxicol 2017; 18 (1): 71.
of decision support. Jt Comm J Qual Patient Saf 2013; 39 (7): 312-8.
P tricular septal defect (VSD) is a rare transthoracic echocardiography (TTE). a VSD complication. It is one of the rare 12. Deilkas ET, Risberg MB, Haugen M, et al. Exploring similarities and differences in 24. Lau I, Kirkwood A. Measuring adverse drug events on hospital medicine units
complication in the era of primary percu- Hemodynamic stabilization, mainly with cases cited in the literature in which the hospital adverse events rates between Norway and Sweden using Global Trigger with the Institute for Healthcare Improvement Trigger Tool: a chart review. Can J
taneous coronary intervention (PCI) [1,2]. the insertion of an intra-aortic balloon transcatheter closure of VSD was per- Tool. BMJ Open 2017; 7 (3): e012492. hosp Pharm 2014; 67 (6): 423-8.
Still, it is associated with a high mortality pump (IABP), is the first step in its clini- formed after 7 days. 13. Rutberg H, Borgstedt-Risberg M, Gustafson P, Unbeck M. Adverse events in 25. Hug BL, Witkowski DJ, Sox CM, et al. Adverse drug event rates in six community
orthopedic care identified via the Global Trigger Tool in Sweden – implications
hospitals and the potential impact of computerized physician order entry for
on preventable prolonged hospitalizations. Patient Saf Surg 2016; 12: 23. prevention. J Gen Intern Med 2009; 25: 31-8.
figure 1. Post-myocardial infarction ventricular A B C
septal defect: a deadly complication Capsule
[A] Transthoracic echocardiogram (TTE) apical Deconstructing probiotics
view showed the presence of a large ventricular
septal defect (VSD) [B] TTE apical view highlighted Besides supporting host metabolism, our intestinal microbiota This process was dependent on intestinal dendritic cells that
with color Doppler showed left-to-right shunt also plays a vital role in modulating functions of immune cells express Toll-like receptor 2. Thus, microbial components, rather
through the VSD [C] The left anterior oblique at a in the gut. Verma and colleagues examined how a particular than live microbes, could potentially be used to treat microbial
45 degree and cranial 25 degree ventriculogram probiotic strain, Bifidobacterium bifidum, promotes the dysbiosis associated with gastrointestinal disorders, including
showed a VSD with sufficient distance from the generation of regulatory T cells (Tregs) in the intestine. β-glucan/ colitis and Crohn’s disease.
apex and a 14 mm defect size [D] The steps of the
percutaneous VSD closure with the insertion of the D galactan polysaccharides derived from the cell wall of B. bifidum Sci Immunol 2018; 3: eaat6975
closure device using a transeptal access via the were responsible for promoting Treg induction in the intestine. Eitan Israeli
transfemoral venous route. The defect was crossed
using a balloon tip catheter, and an Amplatz Super
Stiff TM ST-1 guidewire (Boston Scientific, USA) was Capsule
subsequently positioned in the right pulmonary
artery to advance the 12F delivery system [E]
TM
A 20 mm Amplatzer Post-MI VSD Occluder E F G Cancer chromatin accessibility landscape
(St. Jude Medical, USA) [f] TTE apical view showed The Cancer Genome Atlas (TCGA) provides a high-quality cancer predisposition were revealed, transcription factors and
the device at the level of the interventricular
septum [g] TTE apical view highlighted by color resource of molecular data on a large variety of human enhancers driving molecular subtypes of cancer with patient
Doppler showed a mild residual leak cancers. Corces and co-authors used a recently modified assay survival differences were identified, and non-coding mutations
to profile chromatin accessibility to determine the accessible associated with clinical prognosis were discovered.
chromatin landscape in 410 TCGA samples from 23 cancer
types. When the data were integrated with other omics data Science 2018; 362: eaav1898
available for the same tumor samples, inherited risk loci for Eitan Israeli
720 669